On September 17, Bruker rose 5.52% in regular trading, trading at $64.045/share, with turnover of $47.27 million.

On the news front, multiple major investment banks have significantly raised their price targets for Bruker. UBS adjusted its target from $45 to $65 on September 9 while maintaining a Neutral rating. Earlier, BofA Securities raised its target from $49 to $70. According to FactSet, the current analyst consensus rating is Overweight with a mean price target of $51.58 — a level the stock has now surpassed.

On the fundamentals side, Bruker reported Q2 adjusted earnings of $0.49 per diluted share, representing a 53% year-over-year increase from $0.32, significantly beating the analyst consensus estimate of $0.39. Revenue came in at $838.5 million, up from $797.4 million a year earlier. The company also recently announced strategic initiatives including a collaboration with Luvata on superconductors for fusion projects, a majority investment in Mimetas for disease biology research, and an expanded partnership with Atinary Technologies in AI-driven laboratory automation.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)